Core Insights - Lepu Medical launched a new AI ECG blood pressure monitor on JD Health, which supports 17 types of cardiovascular risk screening and can automatically upload data via 4G network for AI analysis [2][3] - The demand for daily monitoring and early risk screening of cardiovascular health is increasing due to heightened public health awareness, highlighting the need for multifunctional and integrated health solutions [2] - The AI blood pressure monitor features high accuracy in atrial fibrillation detection at 99.97%, allowing users to complete ECG measurements in 30 seconds to 5 minutes [2] Company Overview - Lepu Medical is a leading domestic manufacturer of cardiovascular interventional medical devices, with a strong background in product development and medical data accumulation [2] - The launch of the AI ECG blood pressure monitor represents a significant breakthrough in the integration of medical AI technology within smart medical devices [3] Industry Trends - The introduction of the AI blood pressure monitor marks a new phase in cardiovascular health management, emphasizing the shift towards intelligent AI solutions in healthcare [3] - JD Health aims to establish itself as a premier platform for the online launch of global health products, focusing on creating benchmarks in the medical device category [3]

Core Viewpoint - Lepu Medical announced a cash dividend distribution plan for the first half of 2025, indicating a commitment to returning value to shareholders [2] Summary by Relevant Sections - **Dividend Distribution**: The company will distribute a cash dividend of 1.6275 RMB per 10 shares to all shareholders, based on a total share capital of 1,843,396,086 shares after deducting repurchased shares [2] - **Key Dates**: The record date for the dividend is set for September 22, 2025, and the ex-dividend date is September 23, 2025 [2]

Group 1 - The company announced that it will not lower the conversion price of "Lepu Convertible Bonds 2" during the upcoming two-month period from September 16, 2025, to November 15, 2025 [2] - The board of directors will reconvene after November 16, 2025, to decide on any future adjustments to the conversion price if the relevant conditions are triggered again [2] - The decision reflects the company's strategy to maintain the current conversion price without adjustments for the specified period [2]

证券代码：300003 证券简称：乐普医疗 公告编号：2025-090 债券代码：123108 债券简称：乐普转 2 经深圳证券交易所同意，乐普医疗可转换公司债券于 2021 年 4 月 19 日起 在深圳证券交易所挂牌交易，债券简称"乐普转 2"，债券代码"123108"。转 股期自 2021 年 10 月 8 日至 2026 年 3 月 29 日。 （二）可转债转股价格调整情况 乐普（北京）医疗器械股份有限公司 关于不向下修正"乐普转 2"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、截至 2025 年 9 月 15 日，乐普（北京）医疗器械股份有限公司（以下简 称"公司"）股票已触发"乐普转 2"转股价格向下修正条款。 2、公司于 2025 年 9 月 15 日召开第六届董事会第十七次会议，审议通过了 《关于不向下修正"乐普转 2"转股价格》的议案，公司董事会决定本次不向下 修正"乐普转 2"转股价格，且自董事会审议通过次日起 2 个月内（即 2025 年 9 月 16 日至 2025 年 11 月 15 日），如再次触 ...

| 债券简称：乐普转 债券代码：123108 2 | | | --- | --- | | 证券代码：300003 证券简称：乐普医疗 | 公告编号：2025-088 | 乐普（北京）医疗器械股份有限公司 关于可转债乐普转 2 转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 根据《乐普（北京）医疗器械股份有限公司创业板向不特定对象发行可转换 公司债券募集说明书》（以下简称"《募集说明书》"）发行条款以及中国证券 监督管理委员会（以下简称"中国证监会"）关于可转换公司债券发行的有关规 定，"乐普转 2"在本次发行之后，当公司因送红股、转增股本、增发新股、配 股或派发现金股利等情况（不包括因本次发行的可转债转股增加的股本）使公司 股份发生变化时，将按下述公式进行转股价格的调整（保留小数点后两位，最后 一位四舍五入）： 送股或转增股本：P1=P0/（1+n）； 增发新股或配股：P1=（P0+A×k）/（1+k）； 债券代码：123108 债券简称：乐普转 2 调整前"乐普转 2"转股价格为：27.79 元/股 调整后"乐普转 2"转股价 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300003 | 证券简称：乐普医疗 公告编号：2025-089 | | --- | --- | | 债券代码：123108 | 债券简称：乐普转 2 | 乐普（北京）医疗器械股份有限公司 第六届董事会第十七次会议决议公告 乐普（北京）医疗器械股份有限公司 董事会 乐普（北京）医疗器械股份有限公司（以下简称：公司）第六届董事会第十 七次会议于 2025 年 9 月 15 日在北京市昌平区超前路 37 号公司会议室以现场及 通讯相结合的方式召开，会议通知于 2025 年 9 月 8 日以邮件、电话方式通知全 体董事。会议应出席董事 7 名，实际出席董事 7 名，其中以通讯表决方式出席 会议董事 5 名。本次会议召开符合《公司法》及《公司章程》的相关规定。会议 由董事长蒲忠杰先生主持。出席会议的董事审议并以记名方式投票表决通过了如 下决议： 二〇二五年九月十五日 审议《关于不向下修正"乐普转 2"转股价格》的议案 具体内容详见同日披露于巨潮资讯网（http://www.cninfo.com.cn）的《关 ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-087 乐普（北京）医疗器械股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次权益分派期间，公司可转换公司债券乐普转 2（债券代码：123108） 已暂停转股，截至本公告披露日，公司总股本为 1,880,611,786 股。 2、公司回购专户中的股份不享有利润分配权利。公司将以总股本 1,880,611,786 股扣减已回购股份 37,215,700 股后的股本 1,843,396,086 股为基 数，向全体股东每 10 股派 1.6275 元人民币现金（含税），共计派发现金红利 300,012,713.00 元（含税）。 3、按照上述分红总额，以公司总股本 1,880,611,786 股折算后的分红比例 为每 10 股派发现金红利 1.595293 元，据此计算的除权除息参考价的相关参数 和计算公式如下： 除权除息参考价格=除权除息日的前一交易日收盘价-0.1595293 元/股。 一、权益分派方案实施的基本情况 2、自本次权益 ...

每经头条（nbdtoutiao）——重大突破！中国这款新药，中美官方都认定有突破性疗效！世界肺癌大会 沸腾了 （记者 张喜威） 截至发稿，乐普医疗市值为348亿元。 每经AI快讯，乐普医疗（SZ 300003，收盘价：18.53元）9月15日晚间发布公告称，公司第六届第十七 次董事会会议于2025年9月15日在北京市昌平区超前路37号公司会议室以现场及通讯相结合的方式召 开。 2025年1至6月份，乐普医疗的营业收入构成为：医疗器械占比52.72%，药品占比33.16%，医疗服务及 健康管理占比14.11%。 ...

Core Points - The Bioeconomy Index (970038) closed at 2418.21 points on September 15, with a gain of 0.91% and a trading volume of 34.584 billion yuan, resulting in a turnover rate of 2.15% [1] - Among the index constituents, 21 stocks rose while 29 fell, with Furuide (福瑞股份) leading the gainers at 20.01% and BGI Genomics (华大基因) leading the decliners at 3.11% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (迈瑞医疗) with a weight of 13.82%, latest price at 239.60 yuan, and a market cap of 290.501 billion yuan [1] - Shijia History (十肖史上) with a weight of 4.71%, latest price at 6.84 yuan, and a market cap of 45.404 billion yuan [1] - Tigermed (泰格医药) with a weight of 4.69%, latest price at 61.77 yuan, and a market cap of 53.186 billion yuan [1] - Changchun High-tech (长春高新) with a weight of 4.34%, latest price at 126.81 yuan, and a market cap of 51.731 billion yuan [1] - Kanglong Chemical (康龙化成) with a weight of 3.99%, latest price at 35.90 yuan, and a market cap of 63.837 billion yuan [1] - Muyuan Foods (牧原股份) with a weight of 3.85%, latest price at 58.77 yuan, and a market cap of 321.047 billion yuan [1] - Aimeike (爱美客) with a weight of 3.73%, latest price at 194.07 yuan, and a market cap of 58.724 billion yuan [1] - Lepu Medical (乐普医疗) with a weight of 3.25%, latest price at 18.53 yuan, and a market cap of 34.848 billion yuan [1] - Shenzhen Technology (深科技) with a weight of 3.24%, latest price at 21.88 yuan, and a market cap of 34.292 billion yuan [1] - Jiao Yue Medical (角跃医疗) with a weight of 3.10%, latest price at 38.75 yuan, and a market cap of 38.846 billion yuan [1] Capital Flow Summary - The Bioeconomy Index constituents experienced a net inflow of 645 million yuan from main funds, while retail investors saw a net outflow of 5.51 billion yuan [3] - Notable capital flows include: - Furuide (福瑞股份) with a net inflow of 356 million yuan from main funds [3] - Wens Foodstuffs (温氏股份) with a net inflow of 209 million yuan from main funds [3] - Kanglong Chemical (康龙化成) with a net inflow of 184 million yuan from main funds [3] - Mindray Medical (迈瑞医疗) with a net inflow of 82 million yuan from main funds [3] - Changchun High-tech (长春高新) with a net inflow of 59 million yuan from main funds [3]

Core Viewpoint - Lepu Medical's net profit attributable to shareholders for the first half of 2025 is 691 million yuan, a year-on-year decline of 0.91%, while Q2 net profit reached 312 million yuan, showing a year-on-year growth of 45.05% [1] Financial Performance - The company's revenue in Q2 2025 showed steady growth, with profit growth outpacing revenue growth due to improved gross margin and reduced expense ratio [1] - The cardiovascular interventional business is experiencing stable growth, and the structural heart disease segment is performing exceptionally well [1] Business Adjustments - The inventory destocking in the formulation business is nearly complete, and progress in innovative drug research and development is on track, indicating potential performance improvement in the pharmaceutical segment [1] - Given the completion of business adjustments, the company's profitability is expected to improve, leading to a maintained "buy" rating [1]